VA San Diego Healthcare System 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cysteamine-pantetheine disulfide (TTI-0102) / Thiogenesis Therap
NCT06644534: A Study to Assess TTI-0102 vs Placebo in MELAS Patients

Recruiting
2
12
Europe
TTI-0102, Placebo
Thiogenesis Therapeutics, Inc.
MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
04/26
06/26
NCT05212662: Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Withdrawn
2
60
NA
TTI-0102, cysteamine-pantetheine disulfide, Placebo
Thiogenesis Therapeutics, Inc.
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
09/24
09/24
NCT06990984: A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Not yet recruiting
2
18
NA
TTI-0102: cysteamine-pantetheine disulfide, D-Mannitol
Thiogenesis Therapeutics, Inc.
MELAS Syndrome
09/26
09/26
ACTRN12621000131853p: An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).

Not yet recruiting
1
12
 
Thiogenesis Therapeutics, Inc., Thiogenesis Therapeutics, Inc.
COVID-19
 
 
ACTRN12621000131853: An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).

Completed
1
12
 
Thiogenesis Therapeutics, Inc., Thiogenesis Therapeutics, Inc.
COVID-19
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cysteamine-pantetheine disulfide (TTI-0102) / Thiogenesis Therap
NCT06644534: A Study to Assess TTI-0102 vs Placebo in MELAS Patients

Recruiting
2
12
Europe
TTI-0102, Placebo
Thiogenesis Therapeutics, Inc.
MELAS Syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)
04/26
06/26
NCT05212662: Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19

Withdrawn
2
60
NA
TTI-0102, cysteamine-pantetheine disulfide, Placebo
Thiogenesis Therapeutics, Inc.
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
09/24
09/24
NCT06990984: A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)

Not yet recruiting
2
18
NA
TTI-0102: cysteamine-pantetheine disulfide, D-Mannitol
Thiogenesis Therapeutics, Inc.
MELAS Syndrome
09/26
09/26
ACTRN12621000131853p: An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).

Not yet recruiting
1
12
 
Thiogenesis Therapeutics, Inc., Thiogenesis Therapeutics, Inc.
COVID-19
 
 
ACTRN12621000131853: An interventional study to evaluate the safety, tolerability (how well a substance is tolerated by participants), and Pharmacokinetics (PK, the measure of how the human body processes a substance), of different dosages of TTI-0102 when given to healthy participants as either a single oral dose, or as an oral dose give twice daily on one day (as a potential treatment for COVID-19), compared with a single oral dose of the marketed product Cystagon (registered trademark).

Completed
1
12
 
Thiogenesis Therapeutics, Inc., Thiogenesis Therapeutics, Inc.
COVID-19
 
 

Download Options